Ernesto Pérez Persona-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2023

  1. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

    Hematology (United Kingdom), Vol. 28, Núm. 1

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  2. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

2010

  1. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: Comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

    British Journal of Haematology, Vol. 148, Núm. 1, pp. 110-114

2007

  1. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

    Blood, Vol. 110, Núm. 7, pp. 2586-2592